Tiantian Li1, Licheng Zhu2, Zhonglin Lu1, Na Song3, Ko-Han Lin4, Greta S P Mok1,5,6. 1. Biomedical Imaging Laboratory (BIG), Department of Electrical and Computer Engineering, University of Macau, Macau SAR, China. 2. Department of Computer Science, Faculty of Science and Technology, University of Macau, Macau SAR, China. 3. Department of Nuclear Medicine, Albert Einstein College of Medicine, Yeshiva University, Bronx, New York, USA. 4. Department of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. 5. Faculty of Health Sciences, Institute of Collaborative Innovation, University of Macau, Macau SAR, China. 6. Center for Cognitive and Brain Sciences, Institute of Collaborative Innovation, University of Macau, Macau SAR, China.
Abstract
BACKGROUND: Advance 3D quantitative radionuclide imaging techniques boost the accuracy of targeted radionuclide therapy (TRT) dosimetry to voxel level. The goal of this work is to develop a comprehensive 3D dosimetric software, BIGDOSE, with new features of image registration and virtual CT for patient-specific dosimetry. METHODS: BIGDOSE includes a portable graphical user interface written in Python, integrating (I) input of sequential ECT/CT images; (II) segmentation; (III) non-rigid image registration; (IV) curve fitting and voxel-based integration; (V) dose conversion and (VI) 3D dose analysis. The accuracy of the software was evaluated using a simulation study with 9 XCAT phantoms. We simulated SPECT/CT acquisitions at 1, 12, 24, 72 and 144-hrs post In-111 Zevalin injection with inter-scans misalignments using an analytical projector for medium energy general purpose (MEGP) collimator, modeling attenuation, scatter and collimator-detector response. The SPECT data were reconstructed using quantitative OS-EM method. A CT organ-based registration was performed before the dose calculation. Organ absorbed doses for the corresponding Y-90 therapeutic agent were calculated on target organs and compared with those obtained from OLINDA/EXM, using dose measured from GATE as the gold standard. One patient with In-111 DTPAOC injection as well as two patients with Y-90 microsphere embolization were used to demonstrate the clinical effectiveness of our software. RESULTS: In the simulation, the organ dose errors of BIGDOSE were -9.59%±9.06%, -8.36±5.82%, -23.41%±6.67%, -6.05%±2.06% for liver, spleen, kidneys and lungs, while they were -25.72%±12.52%, -14.93%±10.91%, -28.63%±12.97% and -45.30%±5.84% for OLINDA/EXM. Cumulative dose volume histograms, dose maps and iso-dose contours provided 3D dose distribution information on the simulated and patient data. CONCLUSIONS: BIGDOSE provides a one-stop platform for voxel-based dose estimation with enhanced functions. It is a promising tool to streamline the current clinical TRT dosimetric practice with high accuracy, incorporating 3D personalized imaging information for improved treatment outcome. 2020 Quantitative Imaging in Medicine and Surgery. All rights reserved.
BACKGROUND: Advance 3D quantitative radionuclide imaging techniques boost the accuracy of targeted radionuclide therapy (TRT) dosimetry to voxel level. The goal of this work is to develop a comprehensive 3D dosimetric software, BIGDOSE, with new features of image registration and virtual CT for patient-specific dosimetry. METHODS: BIGDOSE includes a portable graphical user interface written in Python, integrating (I) input of sequential ECT/CT images; (II) segmentation; (III) non-rigid image registration; (IV) curve fitting and voxel-based integration; (V) dose conversion and (VI) 3D dose analysis. The accuracy of the software was evaluated using a simulation study with 9 XCAT phantoms. We simulated SPECT/CT acquisitions at 1, 12, 24, 72 and 144-hrs post In-111 Zevalin injection with inter-scans misalignments using an analytical projector for medium energy general purpose (MEGP) collimator, modeling attenuation, scatter and collimator-detector response. The SPECT data were reconstructed using quantitative OS-EM method. A CT organ-based registration was performed before the dose calculation. Organ absorbed doses for the corresponding Y-90 therapeutic agent were calculated on target organs and compared with those obtained from OLINDA/EXM, using dose measured from GATE as the gold standard. One patient with In-111 DTPAOC injection as well as two patients with Y-90 microsphere embolization were used to demonstrate the clinical effectiveness of our software. RESULTS: In the simulation, the organ dose errors of BIGDOSE were -9.59%±9.06%, -8.36±5.82%, -23.41%±6.67%, -6.05%±2.06% for liver, spleen, kidneys and lungs, while they were -25.72%±12.52%, -14.93%±10.91%, -28.63%±12.97% and -45.30%±5.84% for OLINDA/EXM. Cumulative dose volume histograms, dose maps and iso-dose contours provided 3D dose distribution information on the simulated and patient data. CONCLUSIONS: BIGDOSE provides a one-stop platform for voxel-based dose estimation with enhanced functions. It is a promising tool to streamline the current clinical TRT dosimetric practice with high accuracy, incorporating 3D personalized imaging information for improved treatment outcome. 2020 Quantitative Imaging in Medicine and Surgery. All rights reserved.
Authors: Etienne Garin; Laurence Lenoir; Yan Rolland; Julien Edeline; Habiba Mesbah; Sophie Laffont; Philippe Porée; Bruno Clément; Jean-Luc Raoul; E Boucher Journal: J Nucl Med Date: 2012-02 Impact factor: 10.057
Authors: Stefan Klein; Marius Staring; Keelin Murphy; Max A Viergever; Josien P W Pluim Journal: IEEE Trans Med Imaging Date: 2009-11-17 Impact factor: 10.048
Authors: Yuni K Dewaraja; Scott J Wilderman; Michael Ljungberg; Kenneth F Koral; Kenneth Zasadny; Mark S Kaminiski Journal: J Nucl Med Date: 2005-05 Impact factor: 10.057
Authors: Bin He; Yong Du; W Paul Segars; Richard L Wahl; George Sgouros; Heather Jacene; Eric C Frey Journal: Med Phys Date: 2009-02 Impact factor: 4.071
Authors: Shyam M Srinivas; Navin Natarajan; Joshua Kuroiwa; Sean Gallagher; Elie Nasr; Shetal N Shah; Frank P DiFilippo; Nancy Obuchowski; Bana Bazerbashi; Naichang Yu; Gordon McLennan Journal: Front Oncol Date: 2014-10-13 Impact factor: 6.244
Authors: Lore Santoro; L Pitalot; D Trauchessec; E Mora-Ramirez; P O Kotzki; M Bardiès; E Deshayes Journal: EJNMMI Res Date: 2021-01-04 Impact factor: 3.138